Alnylam gains on positive mid-stage RSV data

Shares of Alnylam surged this morning on the news that mid-stage data for its experimental respiratory drug demonstrated a positive response with statistically significant anti-viral activity. Researchers were testing ALN-RSV01 against respiratory syncytial virus, or RSV, the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age

"We are very pleased with the results of [the study] and look forward to advancing this program to its next stage of development, a Phase II study in naturally infected adult patients which we expect to initiate in the first half of this year," Chief Executive John Maraganore said.

- see this release for more

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.